Debating prostate radiotherapy for metastatic hormone-sensitive #ProstateCancer. @TylerSbrt7 @UCSanDiego joins @l_ballas @CedarsSinai outlining his approach to radiation therapy for the primary tumor in metastatic hormone-sensitive prostate cancer. He summarizes three randomized trials that consistently show a progression-free survival benefit, particularly in patients with low-volume metastatic disease. #WatchNow on UroToday > bit.ly/4t9XGaq @APCCC_Lugano #APCCC26

I don’t really understand this discussion here around PLND as it concerns #PROTEUS. In the Proteus study all patients received per protocol RP with extended PLND. And @declangmurphy didn’t recommend skipping #PLND as far as I heard it during his discussion at #ASCO2026 - he just raised the question whether in the future we may consider re-assessing the need for the adjuvant portion of treatment #ProstateCancer @ASCO @urotoday

#PROTEUS presentation excellently discussed by @declangmurphy focusing on the right aspects to be discussed in early stage #ProstateCancer studies #Enzarad #Proteus next steps to be implemented - including the development of #FFCD Freedom From Clinical Detriment as an endpoint to prove true benefit for patients Thank you for generating visibility for this important upcoming endpoint work @declangmurphy @ChrisSweens1 #ASCO2026 @OncoDailyGU @oncodaily @urotoday

I would still look more in the differences between GS 8 vs 9-10 @ChrisSweens1 which might not have been the same between Enzarad and Proteus and higher in Proteus Imaging might be one minor contributor but I don’t think it would shift Enzarad considerably And surgery - maybe - as a urologist would love to say yes, but probably not ARPI - maybe… #Enzarad #Proteus #ASCO2026 #ProstateCancer

Finally #PROTEUS (#MyBaby) presents results. Significantly improved outcomes reported by Mary-Ellen Taplin for #neoadjuvant/perioperative treatment with #Apalutamide prior to #RadicalProstatectomy PCR/MFS ( based on #PSMAPET), Time to subsequent treatment, to distant mets significantly improved #ProstateCancer #ASCO2026

AMBASSADOR (adjuvant pembro vs placebo) shows a DFS advantage but no OS benefit in adjuvant UC. Today It also shows a non-significant drop in long term in quality of in some parameters such as fatigue but no overall difference in QOL . Almost all trials show the same (marginal or no differences). Are we measuring this optimally? Are our tools fit for purpose. @OncoAlert @apolo_andrea

We are proud to announce the first-ever Upper Tract Urothelial Cancer (#UTUC) Awareness Day! In partnership with @BladderCancerUS, we created #UTUCAwarenessDay to help raise awareness, expand education, and connect those impacted by this complex disease: ir.tyra.bio/news-releases/ne…

#Radiopharmaceuticals in #ProstateCancer Part 1: Current landscape and unmet needs. @boothe_dustin @Utah_Cancer and @PrafulRavi1 @DanaFarber_GU join @DrPhilKantoff @ConvergentRx discussing the clinical positioning of lutetium-177 PSMA in metastatic #CRPC, working through patient selection, sequencing, and progression after Pluvicto. #WatchNow on UroToday > bit.ly/3PBm3Qn

Starting a New Chapter as VP Global Head of Clinical Development at Curium Pharma - @brookmans76 oncodaily.com/career/sabine-… #Cancer #Medicine #Health #Oncology #OncoDaily #MedX #MedNews #MedEd

Appreciate the invitation to join this timely discussion at @FDAOncology Looking forward to tackling important issues in NMIBC trial design and interpretation - risk stratification, the persistent conflation of CIS and papillary disease in trial interpretation, BCG shortages, strain differences ... @chana_weinstock @djmcconkey @garysteinbergmd @h_alahmadie @MaxKates @pjhensley11 @spsutkaMD @pcvblack @FaltasLab @MattGalsky @drdonnahansel @ERPlimackMD @SimaPorten #AUA26 @UTMDAnderson #OncSurgery @IBCG_BladderCA

I am very happy to share that I am starting a new role today, as VP Global Head of Clinical Development at Curium - a deliberate move to re-focus on #ProstateCancer (and beyond) and to expand into #RadioligandTherapy (#RLT) and precision Imaging. At Curium, I’ll be leading global clinical development across the radiopharmaceutical portfolio, from early innovation to registrational strategy. Next up: smarter trials, better patient selection, true integration of diagnostics therapeutics - and most importantly, proving outcomes that meaningfully improve patient benefit. I look forward to working with many of you again! #ProstateCancer #RLT #PSMA #UrologicOncology #ClinicalTrials @oncodaily

As the Clinical Lead at J&J at that time writing the #PROTEUS protocol and defining the specific PET-based MFS endpoint, I am curious to see the final official results at ASCO as well. A few considerations: 🔵 As #PSMA PET imaging was not integrated in the study from the beginning, this endpoint will only be available for a subset of patients 🔵 PET based #MFS is defined in a specific way for PROTEUS as aligned with the FDA - not every positive PET scan counted 🔵 Subsequent therapy is important to consider which is often initiated prior to reaching conventional MFS 🔵 QoL is one key aspect to consider. Concerning erectile function, I’d expect that in cases with nerve sparing surgery and perioperative function (limited subset in a HR setting) recovery will be good ➡️ We will need to consider PROTEUS results together with results from other trials in this early setting including the #BCR setting ➡️ Finally, it will be most important to develop treatment strategies for patients resulting in as much as possible Freedom From Clinical Deterioration (FFCD) with as limited as possible subsequent treatment needed - new endpoints are needed! @ChrisSweens1 @oncodaily @AttardLab @DrPaulNguyen #RadicalProstatectomy #ProstateCancer @TylerSbrt

What is the most established intervention linked to lower biological (epigenetic) age? Exercise A new systematic review @LancetLongevity of 44 studies, >145,000 participants thelancet.com/journals/lanhl…

Thank you Simon! Did a 50th birthday cycling performance test ride today to see whether I get significantly worse at the age of 50 - which was not the case thankfully 😁 I got a table football as a birthday present for my post-cycling workout 🚴‍♀️⚽️❤️ #Cycling #Roadbike #Football #Soccer

Published my first paper without #urology or #oncology but with pure #sportsmedicine/neurological focus in @Muscles_MDPI 👉 A scoping review on Physical Exercise and its effects on cognitive performance and Neurobiological Markers #PhysicalExerciseAsBrainFertilizer #ExerciseAsMedicine ✅ Findings highlight skeletal muscle as an active endocrine and metabolic organ, with acute contraction-induced signaling (e.g., myokines, lactate, catecholamines, BDNF) representing a plausible mechanistic link between exercise and cognitive enhancement ✅ Available evidence positions acute exercise as a reliable, rapidly acting strategy to enhance cognitive performance, with promising implications for learning, occupational functioning, rehabilitation, and healthy aging #PhysicalExercise #Muscle #Learning #HealthyAging #BDNF

Very happy to be on this list of #ProstateCancer opinion leaders @oncodaily Thank you! #UrologicOncology

Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial by Roberto Contieri et al Read the full article: buff.ly/AcADjoA We thank the authors for trusting EUO to publish your work @robertocontieri @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @UroDocAsh @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect